Rondo Therapeutics to Showcase Next-Generation CD28 Bispecific Platform at Upcoming Therapeutic Antibody Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Rondo Therapeutics, a biopharmaceutical company pioneering next-generation bispecific antibodies, announces oral presentations at both Protein & Antibody Engineering Summit (PEGS) and Antibody Engineering & Therapeutics (AET) EU. Rondo Therapeutics will describe its immune-cell engaging bispecific antibody platforms and how it is building a clinical pipeline with a focus on treating solid tumors. The company will provide an update on its lead program, R